The PACIFIC-2 Phase III trial for Imfinzi (durvalumab) concurrently administered with chemoradiotherapy (CRT) did not achieve statistical significance for the primary endpoint of progression-free survival (PFS) versus CRT alone for the treatment…
AstraZeneca’s Imfinzi (durvalumab) has been approved in China for the 1st-line treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine and cisplatin). Imfinzi…
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (Society) today announced that Regeneron is increasing and extending its commitment as the title sponsor of the Regeneron International Science and Engineering Fair (ISEF), the world’s…
GSK plc (LSE/NYSE: GSK) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of momelotinib…
This year the Bayer Foundation is presenting their renowned Hansen Family Award to Professor Claudia Höbartner. The Hansen Family Award is presented alternating with the Otto Bayer Award every second year.…
Bayer today announced at Agritechnica, the world’s leading trade fair for agricultural machinery, an update on the strategic collaboration with Microsoft: New data connectors allow secure, compliant exchange of farm…
Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today presented first-in-human data from a Phase 1 trial investigating AB-1002…
Novo Nordisk invests more than 42 billion Danish kroner in expansion of manufacturing facilities in Kalundborg, Denmark Novo Nordisk today announced plans to invest more than 42 billion Danish kroner…
Roche’s Elecsys NfL test, an important aid for those living with Multiple Sclerosis, is granted FDA Breakthrough Device Designation Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its Elecsys®…
AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity AstraZeneca and Eccogene have entered into an exclusive licence agreement for ECC5004, an investigational oral once-daily glucagon-like peptide…
Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial Positive high-level results from the EMERALD-1 Phase III trial showed…
Bayer and Recursion focus research collaboration on Oncology Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that they have…